Campbell & CO Investment Adviser LLC Takes $524,000 Position in Veradigm Inc. (NASDAQ:MDRX)

Campbell & CO Investment Adviser LLC bought a new stake in shares of Veradigm Inc. (NASDAQ:MDRXFree Report) in the third quarter, HoldingsChannel.com reports. The firm bought 39,850 shares of the software maker’s stock, valued at approximately $524,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of MDRX. Point72 Asset Management L.P. lifted its stake in shares of Veradigm by 13,306.2% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,958,639 shares of the software maker’s stock worth $24,679,000 after purchasing an additional 1,944,029 shares during the period. Westfield Capital Management Co. LP bought a new position in Veradigm in the first quarter worth approximately $19,088,000. Kent Lake Capital LLC purchased a new position in shares of Veradigm during the 2nd quarter worth $10,344,000. Vanguard Group Inc. boosted its stake in shares of Veradigm by 4.4% during the 1st quarter. Vanguard Group Inc. now owns 13,852,474 shares of the software maker’s stock worth $311,957,000 after acquiring an additional 584,339 shares during the last quarter. Finally, Cubist Systematic Strategies LLC grew its position in shares of Veradigm by 370.9% during the 1st quarter. Cubist Systematic Strategies LLC now owns 722,190 shares of the software maker’s stock valued at $9,425,000 after acquiring an additional 568,828 shares during the period.

Veradigm Stock Performance

Shares of Veradigm stock opened at $8.63 on Tuesday. The stock’s 50-day simple moving average is $9.86 and its 200-day simple moving average is $11.93. Veradigm Inc. has a 52 week low of $8.23 and a 52 week high of $17.84.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on MDRX shares. StockNews.com assumed coverage on Veradigm in a research report on Sunday. They set a “hold” rating on the stock. Stephens reaffirmed an “equal weight” rating and set a $13.00 price objective on shares of Veradigm in a research report on Tuesday, November 14th. Royal Bank of Canada cut their price objective on Veradigm from $22.00 to $11.00 and set an “outperform” rating for the company in a research note on Friday, January 19th. Finally, Barclays started coverage on shares of Veradigm in a research note on Wednesday, January 3rd. They set an “equal weight” rating and a $11.00 target price on the stock. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $14.00.

Check Out Our Latest Analysis on MDRX

About Veradigm

(Free Report)

Veradigm Inc, a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions.

Featured Articles

Want to see what other hedge funds are holding MDRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Veradigm Inc. (NASDAQ:MDRXFree Report).

Institutional Ownership by Quarter for Veradigm (NASDAQ:MDRX)

Receive News & Ratings for Veradigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veradigm and related companies with MarketBeat.com's FREE daily email newsletter.